SYN-AKE Research: Molecular Identity, Receptor Mechanisms, and Evidence Limits
Image note: This supplied image is an artistic representation for editorial use and has not been validated as a molecular structure of SYNAKE. Abstract SYNAKE® is the cosmetic trade name commonly associated with dipeptide diaminobutyroyl benzylamide diacetate, a compact synthetic peptidomimetic also described in some cosmetic literature as Tripeptide3. Its commonly reported shorthand is HβAlaProDabNHbenzyl · 2 AcOH, where Dab is 2,4diaminobutyric acid. The material was designed as a functional mimic inspired by Waglerin1, a much larger 22aminoacid peptide from the temple viper, Tropidolaemus wagleri. SYNAKE is not Waglerin1, snake venom, or botulinum toxin. DSMFirmenich describes SYNAKE as an invitroconsidered, reversible antagonist of muscular nicotinic acetylcholine receptors. Its current product page also reports a placebocomparison cosmetic study summary involving 100 volunteers, described as 25 participants per group and a 4% formulated ingredient applied twice daily for four weeks 1. That pagelevel summary is distinguished here from an independent, peerreviewed isolatedcompound trial. The strongest SYNAKEspecific recent publication combines docking and moleculardynamics predictions with antioxidant and limited invitro safety testing; it does not demonstrate receptor blockade in skin or clinical wrinkle efficacy 3. Independent human publications reviewed here evaluated multiingredient topical systems or openlabel formulations, so componentspecific effects cannot be assigned to SYNAKE alone 4 5. 1. Molecular Identity and Naming 1.1 Full Chemical Identity The INCIstyle name Dipeptide Diaminobutyroyl Benzylamide Diacetate describes a modified peptide rather than a simple endogenous signaling peptide. A commonly reported notation is βAlaProDabNHBn · 2 AcOH. βAla contributes a betaalanine unit, Pro is proline, Dab is 2,4diaminobutyric acid, and NHBn is a benzylamide terminus; two acetate equivalents form the diacetate salt. PubChem lists the material as CID 71465152 with molecular formula C₂₃H₃₇N₅O₇ and molecular weight 495.6 2. Naming matters because “dipeptide” in the chemical name and “Tripeptide3” in cosmetic literature can appear contradictory. In context, the compact βAlaProDab motif is often counted as three aminoacidderived units, while the benzylamide and diacetate components are structural modifications. A supplier certificate of analysis, including molecular mass, purity, salt form, and structural confirmation, remains essential when using the trade name in research. 1.2 SYNAKE versus Waglerin1 | Feature | SYNAKE | Waglerin1 | Evidence consequence | ||||| | Molecular identity | Short synthetic peptidomimetic: βAlaProDabNHBn diacetate 2 | 22aminoacid venom peptide from Tropidolaemus wagleri 6 7 | Shared inspiration is not chemical equivalence. | | Biological premise | Manufacturer describes a muscletype nAChR antagonist concept 1 | Competitive antagonist of muscletype nAChRs; receptorselectivity studies exist 6 7 | Naturaltoxin data cannot be transferred directly. | | Use context | Topical cosmetic ingredient | Venomderived research toxin | Route, concentration, delivery, and safety context differ. | | Human evidence | Manufacturer reports a controlled formulation summary; no independent peerreviewed isolatedcompound trial was identified in this review | Not a cosmetic active ingredient | Controlled evidence exists at the manufacturerreported formulation level, but it is not equivalent to independent componentspecific evidence. | 2. Neuromuscular Junction Context 2.1 The nAChR Signaling Concept At the skeletal neuromuscular junction, acetylcholine released from a motor neuron binds muscletype nicotinic acetylcholine receptors, producing ionchannel opening and initiating postsynaptic depolarization. Waglerin1 research established that the natural toxin can competitively antagonize muscle nAChRs with strong subtype and species selectivity 6 7. This biological system provides the conceptual origin for SYNAKE, but it does not establish that a short topical cosmetic analog produces clinically meaningful receptor antagonism after skin application. 2.2 ManufacturerStated Mechanism versus Human Evidence DSMFirmenich states that SYNAKE mimics an essential aminoacid sequence relevant to Waglerin1 functionality and is considered in vitro to antagonize muscular nAChRs. The company describes reversible channel closure, reduced sodium uptake, and a relaxationrelated concept 1. These statements are appropriately reported as a manufacturerstated mode of action. They are not equivalent to an independent demonstration that intact topical SYNAKE reaches facial neuromuscular junctions, occupies receptors at an effective concentration, or alters muscle activity in humans. “In vitro the peptide cosmetic ingredient is considered as an antagonist at the muscular nicotinic acetylcholine receptor (mnAChR).” — DSMFirmenich SYNAKE® product information 1 3. Direct SYNAKE Research 3.1 In Silico MMP and SIRT1 Models Gok, Budama
For research use only. Not for human consumption.